Despite considerable progress in the treatment of T cell acute lymphoblastic leukemia (T-ALL), it is still the highest risk malignancy among ALL. The outcome of relapsed patients remains dismal. The pro-survival role of NOTCH1 and NFkB in T-ALL is well documented; also, both factors were reported to be predictive of relapse.
The NFkB transcription factor family is associated with a broad spectrum of human cancers and inflammatory diseases. It was shown to be required for viability of leukemic cells and recently suggested as a predictor of relapse in T cell acute lymphoblastic leukemia (T-ALL; refs. 1-3). The NOTCH1 signaling pathway, which is commonly activated in T-ALL (4) , was demonstrated to enhance transcriptional function of NFkB via several mechanisms, including transcriptional activation and nuclear retention of the NFkB subunits, activation of upstream regulators, and a mechanism that prevents termination of NFkB signaling (1, 2, 5) .
Combination therapy is the standard approach used to treat T-ALL (6) . Thus, it has been suggested that inhibition of both NOTCH1 and NFkB should be used in combination with existing therapeutic agents (1, 2) . However, the mechanism of action of ionizing radiation and the majority of conventional chemotherapeutic drugs are based on activation of various types of stress, such as DNA damage, mitotic perturbations, and the unfolded protein response. Frequently, NFkB is activated as a part of the stress response and, depending on yet unknown factors, it either protects cells from the drug or mediates apoptosis (7, 8) . Here we report findings from a study in which T-ALL cells responded to NFkB inhibition in opposite ways depending on whether they were treated with a stress-inducing chemotherapeutic agent. Moreover, NOTCH1 enhanced NFkB proapoptotic function in the stressed cells. Our data are in agreement with clinical observations in which T-ALL patients who carry mutations that activate NOTCH1 exhibit a better initial response to treatment (9) , suggesting that mutant NOTCH1 contributes to chemotherapy-induced cell death. Thus, we raise the question: Is it beneficial to inhibit the NOTCH-NFkB pathway in combination with conventional stress-inducing anti-T-ALL therapies?
As examples of stress-inducing therapeutic agents, we used etoposide, bortezomib, and vincristine. Etoposide is a topoisomerase II inhibitor that activates a stress response to DNA double-strand breaks and is a key component of reinduction chemotherapies that are being evaluated to treat relapsed T-ALL patients (10) . Bortezomib, a proteasome inhibitor that activates the unfolded protein response, is also being evaluated clinically for relapsed ALL patients (ClinicalTrials.gov, Identifier NCT00873093). Vincristine is an inhibitor of chromosomal spindle formation that causes stress associated with mitotic perturbations and is a central component of most anti-T-ALL protocols (6) . To inhibit NFkB, we used BMS-345541, a highly selective inhibitor of IkB kinase (IKK), the major upstream regulator of NFkB. BMS-345541 was previously reported to have anti-T-ALL activity (1) . We performed experiments with 5 cell lines derived from T-ALL patient samples: ALL-SIL, K3P, DND-41, HPB-ALL, and Loucy. We measured cell growth with alamarBlue, and apoptosis by annexin-V staining or detection of caspase-3 processing. We correlated the data with the expression levels of selected NFkB target genes and the levels of activation of the IKK complex (by detecting protein levels of the IKK substrate IkBa, which is degraded following phosphorylation) (7).
We found that partial inhibition of the IKK complex counteracted the cytotoxic effects of etoposide, bortezomib, and vincristine. Briefly, Fig. 1A shows growth response as a function of BMS-345541 concentration for 4 of the T-ALLderived cell lines tested. We observed that BMS-345541 treatment alone caused inhibition of growth, consistent with the prosurvival role of NFkB in T-ALL reported by others (1, 2) . However, when the cells were pretreated with etoposide, the response to BMS-345541 was altered: instead of Figure 1 . BMS counteracts ETP effects on cell growth, IKK activation levels, and NFkB target expression. A, alamarBlue cell growth assay (25) . ALL-SIL, DND-41, K3P, and Loucy T-ALL cells, untreated or treated with 5 mM ETP and BMS at the indicated concentrations for 18 hours. P values indicate significant differences in cell counts for ETP-treated cells in the presence of 5 mM BMS (asterisks) versus ETP alone. Measurements were performed in triplicate. Similar results were obtained for DND-41 cells (n ¼ 5) and ALL-SIL cells (n ¼ 2) with different times of incubation, orders of ETP and BMS addition, and sources of serum. B, apoptosis assay (25) . ALL-SIL cells were seeded at 2.5 Â 10 5 /ml, and early and late apoptotic cells were measured by flow cytometry after staining with annexin-PE and 7-AAD. Conditions: control, 0.06% dimethyl sulfoxide; ETP, 10 mM ETP; BMS, 10 mM BMS; and ETPþBMS, 10 mM ETP plus 10 mM BMS. Treatment was administered for 24 hours. A representative graph is shown for 2 biological replicates. Similar results were obtained for K3P cells. C, alamarBlue cell growth assay. DND-41 cells were treated with 5 mM ETP and with 8 mM BMS or 4 mM BAY 11-7082 (BAY) for 18 hours, as indicated. D, IKK kinase assay based on Western blot detection of IkBa degradation in DND-41 cells after 6 hours of treatment as indicated. Left, a representative blot of 3 independent experiments. Right, a quantitative analysis of IkBa levels demonstrating statistically significant partial inhibition of IkBa degradation for ETP-treated cells in the presence of 5 mM BMS (asterisks) versus ETP alone (n ¼ 3). E. DND-41 cells were treated as described in D, and expression of the NFkB targets FAS, BIM, BCLXL, and NFKBIA was determined by qRT-PCR (19) . Experiments were performed in triplicate for 2 biological replicates of 3 cell lines (ALL-SIL, K3P, and DND-41), and similar results were obtained. Student's t-test for all comparisons.
inhibiting growth, BMS-345541 treatment caused an increase in the number of ALL-SIL, K3P, and DND-41 cells, or (in the case of Loucy) had no effect (Fig. 1A) . HPB-ALL cells were resistant to etoposide under the conditions tested (data not shown). We obtained essentially similar results when we measured apoptosis in ALL-SIL cells (Fig. 1B) and used 4 mmol/L BAY 11-7082 (another inhibitor of IkBa phosphorylation) in DND-41 cells (Fig. 1C) . Etoposide was previously reported to activate NFkB (11) . Consistent with this, we observed that etoposide activated the IKK complex (Fig. 1D) , induced RELA nuclear translocation (not shown), and upregulated the NFkB target genes FAS, BCL2L11 (BIM), BCL2L1 (BCLXL), and NFKBIA (Fig. 1E) . Treatment with 5 mmol/L BMS-345541 partially reversed these effects (Fig. 1D and E) . In summary, our data indicate that etoposide-mediated IKK activation contributes to stressinduced T-ALL cell killing; thus, combining IKK inhibitors with etoposide may not be therapeutically beneficial.
Because HPB-ALL was resistant to etoposide under the conditions tested, we examined the effects of treating these cells with bortezomib and vincristine. As an additional approach to inhibit NFkB function, we expressed a transdominant superrepressor form of IkBa (IkB-SR) harboring 2 amino acid substitutions (S32A/S36A) that render it resistant to phosphorylation and degradation, and prevent a signal transfer from IKK to NFkB (12) . Treatment with bortezomib and vincristine gave essentially similar results, consistent with activation of an IKK and NFkB proapoptotic function: BMS-345541 treatment and IkB-SR expression partially reversed the cytotoxic effects of both drugs ( Fig. 2A) . Of interest, the effects of BMS-345541 and IkB-SR expression were cooperative because HPB-ALL cells expressing IkB-SR that were also treated with BMS-345541 were the most resistant to bortezomib or vincristine ( Fig. 2A) . These findings suggest that the mechanism targeted by IKK inhibition may have an NFkB-independent component (7). Bortezomib treatment caused induction of the proapoptotic genes FAS and BIM, and repression of prosurvival BCLXL. These transcriptional responses were attenuated by BMS-345541 treatment and IkB-SR expression (Fig. 2B) . In support of these data, bortezomib was recently shown to activate the IKK-NFkB pathway in other human malignancies (13) . Although our observations indicate that etoposide action is mediated by IKK-NFkB transcriptional activation of apoptotic genes, other topoisomerase II poisons (such as doxorubicin) have been shown to induce IKK-NFkB-dependent apoptosis via repression of BCLXL (11), similar to what we observed for bortezomib. Despite differences in the downstream events, IKK activation contributed to apoptosis induced by all of the above therapeutic agents tested. Thus, inhibition of the IKK Figure 3 . Role of the NOTCH1/MYC-NFkB pathway in T-ALL response to ETP and vincristine. NOTCH1 inhibition prevents the BMS rescue effect. A, left. After pretreatment of ALL-SIL cells in suspension cultures with 1 mM of the g-secretase inhibitor (GSI) Compound E or 0.01% dimethyl sulfoxide for 10 days, cell counts were determined by alamarBlue assay. P value indicates significant difference in the presence of 5 mM BMS (asterisk). A, right. Western blot analysis shows inhibition of activated NOTCH1 and downregulation of MYC protein levels in GSI-treated ALL-SIL cells (19) . NS, nonspecific band. Similar results were obtained for K3P and DND-41 cells. B, DND-41 cells were grown on monolayers for 3 days. The protective effect was more prominent in the case of cells cocultured with OP9-DL1 compared with OP9; 5 mM ETP, 5 mM BMS, 1 mM Compound E as indicated for 18-hour treatment. The experiment was performed in triplicate for 2 biological replicates. C, alamarBlue cell growth assay. Immortalized mouse hematopoietic progenitors overexpressing MYC (18, 19) were treated with vincristine in the presence or absence of 5 mM BMS, 18-hour treatment. GFP is an empty vector-transduced control. The experiment was performed in triplicate; a representative graph is shown. P value indicates significant differences in cell counts at the highest concentration of the drug (asterisk). Student's t-test for all comparisons. D. Expression of NOTCH1 target genes HES1 and MYC inversely correlates with expression of BCL2 and BCLXL prosurvival genes in T-ALL patient samples (23) . Samples were ranked on HES1 levels, and average values for groups of 6 were plotted. The correlation coefficients were determined for 2 independent HES1 probe sets as indicated in Table 1 .
pathway in T-ALL may not provide a therapeutic advantage when combined with these drugs.
To directly test the role of NOTCH1 in the NFkB proapoptotic response, we modulated NOTCH1 signaling by g-secretase inhibition or by coculturing T-ALL cells on OP9-DL1 monolayers presenting the NOTCH1 ligand Delta-like 1 (14) . Briefly, we treated ALL-SIL, K3P, and DND-41 cells with the g-secretase inhibitor Compound E. After several days of treatment, we observed a decrease in etoposide-induced cytotoxicity concomitant with a reduced ability of BMS-345541 to counteract the cytotoxic effects (Fig. 3A) . Thus, our data indicate that IKK's contribution to etoposide-induced T-ALL cell apoptosis is diminished by NOTCH1 inhibition. Conversely, we found that Delta-like 1-mediated activation of NOTCH signaling in OP9-DL1 cocultures enhanced the response to etoposide. BMS-345541 or Compound E treatment partially protected the T-ALL cells from etoposide-induced death under these conditions (Fig. 3B) .
MYC is a downstream target of NOTCH1 in T-ALL (15, 16) . Other studies have shown that enforced expression of MYC in hematopoietic cells enhances sensitivity to etoposide and other stress-inducing therapeutic agents (17) . We observed that overexpression of MYC in immortalized mouse hematopoietic progenitors (18, 19) also increased sensitivity to vincristine (Fig. 3C) . Moreover, the effect was alleviated by BMS-345541, suggesting that the MYC-enhanced response to vincristine is mediated by IKK (Fig. 3C) . In this regard, the cytotoxic effects of vincristine on T-ALL cells were previously shown to be attenuated by g-secretase inhibitor treatment (20) . Although the mechanism remains to be defined, our data indicate that MYC is one of the downstream components of NOTCH signaling that contribute to the NFkB proapoptotic response to chemotherapy. Of note, activation of the IKK-NFkB pathway by vincristine was previously implicated in the induction of apoptotic cell death in other human tumor types; moreover, the investigators showed that glucocorticoids, which are known to partially act via inhibition of NFkB, attenuated vincristineinduced death (21) . These findings might explain why additional courses of vincristine and dexamethasone combination therapy did not result in improved treatment outcomes in a recent worldwide survey of T-ALL clinical trials (22) . Therefore, our data suggest that NOTCH1 or MYC activation levels are potential candidates to predict the apoptotic role of NFkB in response to stress-inducing chemotherapy. We analyzed publicly available microarray profiling data from 92 T-ALL patients (23) . We plotted the expression levels of HES1 as a measure of NOTCH1 pathway activation versus prosurvival BCL2 and BCLXL expression levels and found that they were inversely correlated throughout the range of NOTCH1 activation (Fig. 3D) . As expected, HES1 mRNA levels directly correlated with MYC mRNA levels, consistent with findings that NOTCH1 induces MYC expression in T-ALL cells (15, 16) . These correlations support the notion that when NOTCH1 is activated, the balance of NFkB targets may shift toward an apoptotic outcome.
Despite an overall cure rate of 80% in children, the overall survival of adult ALL patients is only $35% (6). For both patient populations, relapse remains a serious problem in T-ALL. The fate of relapsed patients is dismal. Historically, to prevent relapse, T-ALL patients underwent an aggressive combination therapy that was so intense that toxicity became a significant cause of unfavorable outcome (24) . New, more effective therapeutic agents and a better understanding of their compatibility with existing drugs are needed. We found that under the conditions examined in our study chemotherapy-induced stress changed the function of the NOTCH-NFkB signaling pathway in T-ALL cell lines from prosurvival to proapoptotic. Thus, the data argue strongly for further studies of the circumstances that determine NFkB action in T-ALL patients on different treatment protocols, and the impact of activating NOTCH1 mutations. 
